Details of the Drug

General Information of Drug (ID: DMEH7YU)

Drug Name

Lanadelumab

Synonyms

Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930

Indication

Disease Entry	ICD 11	Status	REF
Hereditary angioedema	4A00.14	Approved	[1]

Affected Organisms

Humans

ATC Code

B06AC05: Lanadelumab

B06AC: Drugs used in hereditary angioedema

B06A: OTHER HEMATOLOGICAL AGENTS

B06: OTHER HEMATOLOGICAL AGENTS

B: BLOOD AND BLOOD FORMING ORGANS

Sequence

>heavy chain
EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
>light chain
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPS
RFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4 h []
Bioavailability: The bioavailability of drug is 80% []
Clearance: The total plasma clearance of drug is 18-25 mL/h [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 13.8 - 15 days [2]
Metabolism: The drug is metabolized via proteolytic enzymes []
Vd: The volume of distribution (Vd) of drug is 12-16 L [3]

Cross-matching ID

UNII: 2372V1TKXK
DrugBank ID: DB14597
TTD ID: D08LEY

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasma kallikrein (KLKB1)	TTMF8H9	KLKB1_HUMAN	Modulator	[1]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. N Engl J Med. 2017 Feb 23;376(8):717-728. doi: 10.1056/NEJMoa1605767.
3	Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R, TenHoor C, Stolz LE, Stevens C, Biedenkapp J, Adelman B: A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014 Oct;113(4):460-6.e2. doi: 10.1016/j.anai.2014.05.028. Epub 2014 Jun 26.